Liquid biopsy enters the clinic—implementation issues and future challenges
Historically, studies of disseminated tumour cells in bone marrow and circulating tumour
cells in peripheral blood have provided crucial insights into cancer biology and the …
cells in peripheral blood have provided crucial insights into cancer biology and the …
Liquid biopsy: from discovery to clinical application
Over the past 10 years, circulating tumor cells (CTC) and circulating tumor DNA (ctDNA)
have received enormous attention as new biomarkers and subjects of translational research …
have received enormous attention as new biomarkers and subjects of translational research …
Epigenetics, fragmentomics, and topology of cell-free DNA in liquid biopsies
BACKGROUND Liquid biopsies that are based on analysis of cell-free DNA from plasma
offer diagnostic information that is otherwise accessible conventionally through invasive …
offer diagnostic information that is otherwise accessible conventionally through invasive …
Detection and characterization of lung cancer using cell-free DNA fragmentomes
D Mathios, JS Johansen, S Cristiano, JE Medina… - Nature …, 2021 - nature.com
Non-invasive approaches for cell-free DNA (cfDNA) assessment provide an opportunity for
cancer detection and intervention. Here, we use a machine learning model for detecting …
cancer detection and intervention. Here, we use a machine learning model for detecting …
Clinical relevance of blood-based ctDNA analysis: mutation detection and beyond
Cell-free DNA (cfDNA) derived from tumours is present in the plasma of cancer patients. The
majority of currently available studies on the use of this circulating tumour DNA (ctDNA) deal …
majority of currently available studies on the use of this circulating tumour DNA (ctDNA) deal …
Inferring gene expression from cell-free DNA fragmentation profiles
Profiling of circulating tumor DNA (ctDNA) in the bloodstream shows promise for
noninvasive cancer detection. Chromatin fragmentation features have previously been …
noninvasive cancer detection. Chromatin fragmentation features have previously been …
Deep whole-genome ctDNA chronology of treatment-resistant prostate cancer
Circulating tumour DNA (ctDNA) in blood plasma is an emerging tool for clinical cancer
genoty** and longitudinal disease monitoring. However, owing to past emphasis on …
genoty** and longitudinal disease monitoring. However, owing to past emphasis on …
Clinical application of advanced multi-omics tumor profiling: Sha** precision oncology of the future
D Akhoundova, MA Rubin - Cancer Cell, 2022 - cell.com
Next-generation DNA sequencing technology has dramatically advanced clinical oncology
through the identification of therapeutic targets and molecular biomarkers, leading to the …
through the identification of therapeutic targets and molecular biomarkers, leading to the …
Liquid biopsy-based biomarkers of treatment response and resistance
Predictive biomarkers aid selection of personalized therapy targeted to molecular alterations
within an individual's tumor. Patients' responses to targeted therapies are commonly …
within an individual's tumor. Patients' responses to targeted therapies are commonly …
Detecting liver cancer using cell-free DNA fragmentomes
Liver cancer is a major cause of cancer mortality worldwide. Screening individuals at high
risk, including those with cirrhosis and viral hepatitis, provides an avenue for improved …
risk, including those with cirrhosis and viral hepatitis, provides an avenue for improved …